Section of Medical Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 72%
3. Non-Small Cell Lung Carcinoma 68%
4. Survival 61%
5. Therapeutics 59%
6. Drug Therapy 55%
7. Progression-Free Survival 46%
8. Rituximab 41%
9. Hodgkin Disease 31%
10. Mantle-Cell Lymphoma 30%
11. Mutation 30%
12. Non-Hodgkin's Lymphoma 29%
13. Sarcoma 26%
14. Lung Neoplasms 26%
15. Immunotherapy 26%
16. Lymphoma, Large B-Cell, Diffuse 25%
17. Radiotherapy 25%
18. T-Lymphocytes 24%
19. Brentuximab Vedotin 23%
20. Follicular Lymphoma 23%
21. Clinical Trials 23%
22. Recurrence 23%
23. Triple Negative Breast Neoplasms 22%
24. Lymphoma 22%
25. Neoplasm Metastasis 22%
26. Doxorubicin 20%
27. Prostatic Neoplasms 20%
28. Safety 20%
29. Docetaxel 19%
30. gemcitabine 19%
31. Carboplatin 19%
32. Glioblastoma 19%
33. Adenocarcinoma 18%
34. Proteins 18%
35. Cyclophosphamide 18%
36. Confidence Intervals 17%
37. Pancreatic Neoplasms 17%
38. pembrolizumab 17%
39. Transplants 17%
40. Paclitaxel 17%
41. Guidelines 17%
42. Bendamustine Hydrochloride 16%
43. Cisplatin 16%
44. Genes 16%
45. B-Cell Lymphoma 16%
46. Genome 16%
47. Circulating Tumor DNA 16%
48. Melanoma 15%
49. DNA 15%
50. Squamous Cell Carcinoma of Head and Neck 15%
51. Biomarkers 14%
52. Bevacizumab 14%
53. Small Cell Lung Carcinoma 14%
54. Radiation 14%
55. Peripheral T-Cell Lymphoma 14%
56. Renal Cell Carcinoma 13%
57. Cetuximab 13%
58. Squamous Cell Carcinoma 13%
59. Carcinoma 13%
60. Pemetrexed 13%
61. Bortezomib 12%
62. Maintenance 12%
63. Estrogen Receptors 12%
64. Growth 12%
65. Multiple Myeloma 12%
66. Lenalidomide 12%
67. Breast 12%
68. Vincristine 11%
69. 130-nm albumin-bound paclitaxel 11%
70. B-Cell Chronic Lymphocytic Leukemia 11%
71. Etoposide 11%
72. Neoadjuvant Therapy 11%
73. PCI 32765 11%
74. Placebos 11%
75. Platinum 11%
76. Maximum Tolerated Dose 11%
77. Hormones 10%
78. Colorectal Neoplasms 10%
79. Neurofibrosarcoma 10%
80. Prednisone 10%
81. Positron-Emission Tomography 10%
82. Stem Cells 10%
83. HIV 10%
84. Nivolumab 10%
85. Stem Cell Transplantation 10%
86. palbociclib 9%
87. Kenya 9%
88. Erythropoietin Receptors 9%
89. ErbB Receptors 9%
90. Heterografts 9%
91. Cell Transplantation 9%
92. Population 9%
93. Head and Neck Neoplasms 9%
94. Neutropenia 9%
95. Bone Marrow 9%
96. High-Throughput Nucleotide Sequencing 9%
97. Everolimus 8%
98. DNA Damage 8%
99. Erlotinib Hydrochloride 8%
100. Macrophages 8%